ER
VNDA icon

Enlightenment Research’s Vanda Pharmaceuticals VNDA Stock Holding History

Enlightenment Research’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$5K – 658
2018
Q4 		$5K Buy
+200
New +$4.7K 0.01% 700

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Enlightenment Research's VNDA Position: Q1 2019 in Review

Enlightenment Research sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 200 shares — an estimated $5K sold.

Enlightenment Research first reported a position in VNDA in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • Enlightenment Research reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 200 Vanda Pharmaceuticals shares in Q1 2019, an estimated $5K.
  • Enlightenment Research first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Vanda Pharmaceuticals position peaked at $5K in Q4 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.